All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Results from a global phase Ib study of JNJ-90014496 in patients with relapsed/refractory large B-cell lymphoma
Do you know... JNJ-90014496 is an investigational CAR T-cell therapy for the treatment of relapsed/refractory large B-cell lymphoma. Which of the following antigens does it target?
At the European Hematology Association (EHA) 2025 Congress and the 18th International Conference on Malignant Lymphoma (ICML) Matthew Ku, and Krish Patel, respectively, discussed the first results from a phase Ib study (NCT05421663) investigating JNJ-90014496 (formerly C-CAR039), a CD19/CD20 bispecific chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed/refractory large B-cell lymphoma (N = 51). 75 M CAR+ T-cells was selected as the recommended phase II dose, with an overall response rate and complete response rate of 96% and 77%, respectively.
This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your experience, when do most CRS/ICANS events occur after lisocabtagene maraleucel infusion?
